Researcher Spotlight: Gonzalo Blanco Ares, PhD THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH Bruce D. Cheson, MD Fellow Care of patients with chronic lymphocytic leukemia (CLL) is complicated by the immunodeficiency that is associated with the disease, which can lead to…
Researcher Spotlight: Erin Parry, MD, PhD DANA-FARBER CANCER INSTITUTE Dr. Parry’s research is centered at the intersection of genomics and cancer immunotherapy, with a focus on B cell lymphomas. Her LRF research project is aimed at understanding the processes that…
Researcher Spotlight: Christine Ryan, MD DANA-FARBER CANCER INSTITUTE Kanti R. Rai, MD Clinical Scholar Richter’s transformation (RT) represents a devastating progression of chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL) into an aggressive B-cell lymphoma. Prognosis with RT is…
Researcher Spotlight: Daniel Ermann, MD THE UNIVERSITY OF UTAH Patients with chronic lymphocytic leukemia (CLL) are at increased risk for infections due to the immune dysfunction associated with the disease. Bacterial pneumonia is a particular concern, and while vaccination with…
Researcher Spotlight: BOYU HU, MD THE UNIVERSITY OF UTAH Some patients with chronic lymphocytic leukemia (CLL) respond poorly to treatment due to genetic changes that affect primary DNA damage repair (DDR) mechanisms targeted by currently approved agents. Instead, the CLL…
Oral Therapy and Adherence in Lymphoma An increasing number of lymphoma and chronic lymphocytic leukemia (CLL) patients receive their chemotherapy not from intravenous (IV) treatments administered in a hospital or clinic, but via a pill, taken at home on a…
Researcher Spotlight: Boyu Hu, MD University of Utah/Huntsman Cancer Institute Gene mutations and chromosomal alterations found in relapsed/refractory chronic lymphocytic leukemia (CLL) makes the disease more resistant to currently approved therapies and prone to earlier relapses. While these gene changes…
Researcher Spotlight: Paolo Strati, MD The University of Texas Macrophages are large white blood cells that present antigens within the human immune system, an important step in signaling the immune system to attack disease,. Researchers are developing therapies which help increase the activity…
Researcher Spotlight: Rahul Lakhotia, MBBS National Institutes of Health Indolent lymphomas frequently require multiple lines of treatment as the disease recurs; the frequency of treatment makes it important to balance efficacy with potential toxicities (side effects). Dr. Lakhotia’s LCRMP project tests a new…
Researcher Spotlight: Teresa Sadras, PhD Beckman Research Institute City of Hope Though chronic lymphocytic leukemia (CLL) patients with indolent (slow-growing) forms of the disease have a high rates of long-term survival, patients with more aggressive forms of CLL have significantly…